Treatment of Parkinson's disease with the ergoline derivatives CQ 32-084 and CU 32-085.
Two alpha-aminoergolines with different dopaminergic effects in rats were tried in two groups of Parkinson patients. CQ 32-084 was given in increasing doses up to 10 mg a day for 4 weeks to 10 Parkinson patients, 6 untreated cases and 4 cases with long-term levodopa treatment problems. The patients were checked every week by the Webster rating scale. All patients improved more or less, the earlier untreated patients more than the levodopa-treated patients. Most patients stopped at a dose of 15 mg a day. The side effects were slight. Another group of 10 patients with long-term levodopa treatment problems or insufficient effect of actual treatment were treated in a double-blind crossover trial with another ergoline derivative, CU 32-085. The dose was increased as in the first experiment up to 20 mg a day. Seven of the patients improved during the active drug period. In three cases, the hyperkinesia was increased during the active period, and in two cases it improved. Three patients found an obvious antidepressive effect during the active drug period. Five patients indicated slight decrease of on/off phenomena during the active period of treatment. A more extensive examination of these drugs seems indicated.